US6355681B2
(en)
*
|
1995-12-07 |
2002-03-12 |
Glytech, Inc. |
Glycine substitutes and precursors for treating a psychosis
|
US6512010B1
(en)
*
|
1996-07-15 |
2003-01-28 |
Alza Corporation |
Formulations for the administration of fluoxetine
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
PT1073432E
(pt)
*
|
1998-04-14 |
2007-10-22 |
Gen Hospital Corp |
Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
|
BR9914419A
(pt)
*
|
1998-10-16 |
2001-06-26 |
Janssen Pharmaceutica Nv |
Terapia para melhoria da percepção
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
DE19918105C1
(de)
*
|
1999-04-22 |
2000-09-21 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum
|
US7146209B2
(en)
*
|
2000-05-08 |
2006-12-05 |
Brainsgate, Ltd. |
Stimulation for treating eye pathologies
|
AU2001286763C1
(en)
*
|
2000-08-25 |
2006-03-02 |
Research Corporation Technologies, Inc. |
New uses for amino acid anticonvulsants for treatment of pain
|
CA2427388C
(en)
*
|
2000-11-01 |
2011-12-20 |
Sention, Inc. |
Pharmaceutical compositions and uses for improving memory and learning impairments
|
US20070117869A1
(en)
*
|
2000-11-01 |
2007-05-24 |
Cognition Pharmaceuticals Llc |
Methods for treating coginitive impairment and improving cognition
|
US20050059743A1
(en)
*
|
2000-11-01 |
2005-03-17 |
Sention, Inc. |
Methods for treating mild cognitive impairment and alzheimer's disease
|
US20030119884A1
(en)
*
|
2000-11-01 |
2003-06-26 |
Epstein Mel H. |
Methods and compositions for regulating memory consolidation
|
US20030232890A1
(en)
*
|
2000-11-01 |
2003-12-18 |
Sention, Inc. |
Methods for treating an impairment in memory consolidation
|
US7619005B2
(en)
*
|
2000-11-01 |
2009-11-17 |
Cognition Pharmaceuticals Llc |
Methods for treating cognitive impairment in humans with Multiple Sclerosis
|
US20020155170A1
(en)
*
|
2000-11-30 |
2002-10-24 |
Walsh William John |
Nutrient supplements and methods for treating autism and for preventing the onset of autism
|
US20030185754A1
(en)
*
|
2001-01-16 |
2003-10-02 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
US20030166554A1
(en)
*
|
2001-01-16 |
2003-09-04 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
WO2005016319A2
(en)
*
|
2003-08-06 |
2005-02-24 |
Emory University |
Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
|
US7750030B2
(en)
|
2001-03-29 |
2010-07-06 |
Michael Davis |
Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
|
AU2002256422A1
(en)
*
|
2001-05-02 |
2002-11-11 |
Blanchette Rockefeller Neurosciences Institute |
Carbonic anhydrase activators for enhancing learning and memory
|
EP1935414A3
(en)
*
|
2001-05-02 |
2010-08-18 |
Blanchette Rockefeller Neurosciences Institute |
Carbonic anhydrase activators for enhancig learning and memory
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
EP1392262A1
(en)
|
2001-05-24 |
2004-03-03 |
Alexza Molecular Delivery Corporation |
Delivery of drug esters through an inhalation route
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
US7498019B2
(en)
|
2001-05-24 |
2009-03-03 |
Alexza Pharmaceuticals, Inc. |
Delivery of compounds for the treatment of headache through an inhalation route
|
US7766013B2
(en)
|
2001-06-05 |
2010-08-03 |
Alexza Pharmaceuticals, Inc. |
Aerosol generating method and device
|
US7645442B2
(en)
|
2001-05-24 |
2010-01-12 |
Alexza Pharmaceuticals, Inc. |
Rapid-heating drug delivery article and method of use
|
US7005138B2
(en)
*
|
2001-12-21 |
2006-02-28 |
Duramed Pharmaceuticals, Inc. |
Method of systematically delivering SSRIs
|
EP1575478A2
(en)
*
|
2001-12-28 |
2005-09-21 |
Teva Pharmaceutical Industries Ltd. |
A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
|
BE1015608A6
(fr)
*
|
2003-07-15 |
2005-06-07 |
Messadek Jallal |
Traitement des arterites.
|
AU2003211940A1
(en)
*
|
2002-02-14 |
2003-09-04 |
Ajinomoto Co., Inc. |
Drugs for mitochondrial diseases
|
JP2005527525A
(ja)
*
|
2002-03-15 |
2005-09-15 |
ハー・ルンドベック・アクチエゼルスカベット |
神経学的及び精神医学的障害の治療にasc−1阻害剤を使用する方法
|
US7684859B2
(en)
*
|
2002-04-25 |
2010-03-23 |
Brainsgate Ltd. |
Stimulation of the OTIC ganglion for treating medical conditions
|
US7636597B2
(en)
*
|
2002-11-14 |
2009-12-22 |
Brainsgate, Ltd. |
Surgical tools and techniques for stimulation
|
JP2005531305A
(ja)
*
|
2002-06-10 |
2005-10-20 |
エヴォテック ニューロサイエンシス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ステロイド産生急性調節タンパク質の神経変性疾患に関する診断的および治療的使用
|
KR100446503B1
(ko)
*
|
2002-06-19 |
2004-09-04 |
삼성전자주식회사 |
복합 억세스 포인트 장치 및 복합 억세스 포인트 장치를이용한 음성/데이터 패킷 처리 방법
|
WO2004005935A1
(ja)
*
|
2002-07-04 |
2004-01-15 |
Mitsubishi Pharma Corporation |
統合失調症の検査、診断方法
|
MXPA05000294A
(es)
|
2002-07-30 |
2005-08-19 |
Peter Migaly |
Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
|
FR2843590B1
(fr)
*
|
2002-08-14 |
2007-10-05 |
Prestwick Scient Capital Inc |
Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
|
US9174975B2
(en)
*
|
2002-08-22 |
2015-11-03 |
Sumitomo Dainippon Pharma Co., Ltd |
Remedy for integration dysfunction syndrome
|
US7160913B2
(en)
|
2002-09-13 |
2007-01-09 |
Thomas Jefferson University |
Methods and kit for treating Parkinson's disease
|
US20040067986A1
(en)
*
|
2002-10-04 |
2004-04-08 |
Nathan Sassover |
Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
|
WO2004037289A2
(en)
*
|
2002-10-25 |
2004-05-06 |
Pfizer Products Inc. |
Novel injectable depot formulations
|
TWI319713B
(en)
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
US20040105818A1
(en)
|
2002-11-26 |
2004-06-03 |
Alexza Molecular Delivery Corporation |
Diuretic aerosols and methods of making and using them
|
US7913688B2
(en)
|
2002-11-27 |
2011-03-29 |
Alexza Pharmaceuticals, Inc. |
Inhalation device for producing a drug aerosol
|
ATE376419T1
(de)
|
2002-12-27 |
2007-11-15 |
Otsuka Pharma Co Ltd |
Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
|
AR042806A1
(es)
*
|
2002-12-27 |
2005-07-06 |
Otsuka Pharma Co Ltd |
Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
|
US20070249537A1
(en)
*
|
2003-01-23 |
2007-10-25 |
Supernus Pharmaceuticals, Inc. |
Absorption enhancing agents
|
IL154318A
(en)
|
2003-02-06 |
2010-05-31 |
Sarah Herzog Memorial Hospital |
Pharmaceutical compositions for the treatment of movement disorders
|
ATE347358T1
(de)
*
|
2003-04-17 |
2006-12-15 |
Jallal Messadek |
Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
|
BRPI0410378A
(pt)
*
|
2003-05-16 |
2006-06-13 |
Pfizer Prod Inc |
tratamento de distúrbios psicóticos e depressivos
|
EP1625334B9
(en)
|
2003-05-21 |
2012-07-25 |
Alexza Pharmaceuticals, Inc. |
Percussively ignited self-contained heating unit
|
WO2004112700A2
(en)
*
|
2003-06-06 |
2004-12-29 |
The General Hospital Corporation |
Methods and compositions for modulating amyloid precursor protein translation
|
CA2531980C
(en)
|
2003-06-23 |
2013-09-17 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imide derivatives as therapeutic agents for senile dementia
|
NZ527142A
(en)
*
|
2003-07-23 |
2006-03-31 |
Douglas Pharmaceuticals Ltd |
A stable suspension formulation
|
US7838029B1
(en)
*
|
2003-07-31 |
2010-11-23 |
Watson Laboratories, Inc. |
Mirtazapine solid dosage forms
|
US20060128657A1
(en)
*
|
2003-08-04 |
2006-06-15 |
Jallal Messadek |
Selected betaines and their uses
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
EP1713486A4
(en)
*
|
2003-12-02 |
2009-04-29 |
Sheldon Leslie James |
COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
|
WO2005062894A2
(en)
*
|
2003-12-23 |
2005-07-14 |
Darpharma, Inc. |
Co-administration of dopamine-receptor binding compounds
|
JP2007517049A
(ja)
*
|
2003-12-29 |
2007-06-28 |
マクデビット、ジェイソン |
再発性病状を治療するための組成物および方法
|
US20120225916A1
(en)
*
|
2003-12-29 |
2012-09-06 |
Mcdevitt Jason P |
Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
|
US20050171088A1
(en)
*
|
2004-01-30 |
2005-08-04 |
Astrazeneca Ab |
Treatment of psychoses with dibenzothiazepine antipsychotic
|
US8010189B2
(en)
*
|
2004-02-20 |
2011-08-30 |
Brainsgate Ltd. |
SPG stimulation for treating complications of subarachnoid hemorrhage
|
US9233245B2
(en)
|
2004-02-20 |
2016-01-12 |
Brainsgate Ltd. |
SPG stimulation
|
WO2005080976A1
(ja)
|
2004-02-20 |
2005-09-01 |
Dainippon Sumitomo Pharma Co., Ltd. |
統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法
|
US8055347B2
(en)
|
2005-08-19 |
2011-11-08 |
Brainsgate Ltd. |
Stimulation for treating brain events and other conditions
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
US20050209317A1
(en)
*
|
2004-03-22 |
2005-09-22 |
Apkarian A V |
Method and compositions for treatment of chronic neuropathic pain
|
TW200538181A
(en)
|
2004-05-18 |
2005-12-01 |
Brni Neurosciences Inst |
Treatment of depressive disorders
|
US20050261278A1
(en)
|
2004-05-21 |
2005-11-24 |
Weiner David M |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
US20050277626A1
(en)
*
|
2004-05-27 |
2005-12-15 |
Neurocure Ltd. |
Methods and compositions for treatment of nicotine dependence and dementias
|
US7540286B2
(en)
|
2004-06-03 |
2009-06-02 |
Alexza Pharmaceuticals, Inc. |
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
|
EP1604656A1
(en)
|
2004-06-09 |
2005-12-14 |
Schwarz Pharma Ag |
Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
|
JP2008504295A
(ja)
*
|
2004-06-25 |
2008-02-14 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
注意欠陥多動性障害及び高フェニルアラニン血症の治療のための方法及び組成物
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
US20060039867A1
(en)
*
|
2004-08-20 |
2006-02-23 |
Cypress Bioscience, Inc. |
Method for treating sleep-related breathing disorders with setiptiline
|
US20090299418A1
(en)
*
|
2004-08-23 |
2009-12-03 |
Brainsgate Ltd. |
Concurrent bilateral spg modulation
|
WO2006034196A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Lifelike Biomatic Inc. |
Compositions for enhancing memory and methods therefor
|
WO2006050581A2
(en)
*
|
2004-11-10 |
2006-05-18 |
Jallal Messadek |
Betaine as agent against arthropod - or mosquito -borne diseases
|
US20060122127A1
(en)
*
|
2004-11-17 |
2006-06-08 |
Cypress Bioscience, Inc. |
Methods for reducing the side effects associated with mirtzapine treatment
|
WO2006060186A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives for the treatment of dementia and related disorders
|
EP1830833B1
(en)
*
|
2004-12-16 |
2010-01-27 |
Janssen Pharmaceutica N.V. |
Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof
|
CA2592345C
(en)
|
2004-12-21 |
2013-09-24 |
Merck Sharp & Dohme Limited |
Piperidine and azetidine derivatives as glyt1 inhibitors
|
AU2006258842B2
(en)
*
|
2005-06-13 |
2011-09-15 |
Merck Sharp & Dohme Limited |
Therapeutic agents
|
WO2007006157A1
(en)
*
|
2005-07-14 |
2007-01-18 |
The University Of British Columbia |
Neuroprotective modulation of nmda receptor subtype activities
|
BRPI0615860B8
(pt)
*
|
2005-09-09 |
2021-05-25 |
Labopharm Barbados Ltd |
composição farmacêutica de liberação prolongada monolítica sólida
|
ES2382818T3
(es)
|
2005-09-29 |
2012-06-13 |
Merck Sharp & Dohme Corp. |
Inhibidores de transportadores glicina radiomarcados
|
PE20080126A1
(es)
*
|
2006-03-24 |
2008-04-07 |
Wyeth Corp |
Metodos para tratar trastornos cognitivos y otros afines
|
US7884124B2
(en)
|
2006-06-30 |
2011-02-08 |
Sepracor Inc. |
Fluoro-substituted inhibitors of D-amino acid oxidase
|
TW200820963A
(en)
*
|
2006-07-28 |
2008-05-16 |
Xenoport Inc |
Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
|
US20090210026A1
(en)
*
|
2006-08-17 |
2009-08-20 |
Brainsgate Ltd. |
Spg stimulation for enhancing neurogenesis and brain metabolism
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
US20100129805A1
(en)
*
|
2006-11-09 |
2010-05-27 |
Wai Lun Alan Fung |
Slc1a1 antipsychotic drug response markers
|
US20080216828A1
(en)
|
2007-03-09 |
2008-09-11 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
WO2008118785A2
(en)
*
|
2007-03-23 |
2008-10-02 |
Tikvah Therapeutics |
Methods for treating depression using immediate-impact treatments and d-cycloserine
|
WO2008124814A2
(en)
*
|
2007-04-10 |
2008-10-16 |
Mcdevitt Jason P |
Sublingual formulations of d-cycloserine and methods of using same
|
WO2008128166A1
(en)
*
|
2007-04-13 |
2008-10-23 |
Concert Pharmaceuticals Inc. |
Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
|
EP2167096A4
(en)
*
|
2007-06-13 |
2010-07-14 |
Cypress Bioscience Inc |
IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
|
US8580776B2
(en)
*
|
2007-07-10 |
2013-11-12 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods for treating neurodegenerating diseases
|
WO2009018368A1
(en)
*
|
2007-07-30 |
2009-02-05 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
|
US7860569B2
(en)
|
2007-10-18 |
2010-12-28 |
Brainsgate, Ltd. |
Long-term SPG stimulation therapy for prevention of vascular dementia
|
WO2009065193A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Jallal Messadek |
Treatment of aspirin resistance with betaine and/or betaine enriched molasses
|
IL188681A0
(en)
*
|
2008-01-09 |
2008-12-29 |
Amino Acid Solutions Inc |
Pharmaceutical compositions and methods utilizing a d-amino acid
|
EP2111858A1
(en)
*
|
2008-04-25 |
2009-10-28 |
EPFL Ecole Polytechnique Fédérale de Lausanne |
Novel treatment for alzheimer's disease
|
GB0817379D0
(en)
*
|
2008-09-23 |
2008-10-29 |
Merck Sharp & Dohme |
New use
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US8355927B2
(en)
|
2010-11-05 |
2013-01-15 |
Genomind, Llc |
Neuropsychiatric test reports
|
US20110237537A1
(en)
*
|
2009-05-29 |
2011-09-29 |
Lombard Jay L |
Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
|
TWI473624B
(zh)
*
|
2009-09-14 |
2015-02-21 |
Shiseido Co Ltd |
D-methionine and its salts are used in the manufacture of methods for reducing the UV damage composition
|
TWI544923B
(zh)
*
|
2009-12-29 |
2016-08-11 |
何應瑞 |
用於治療神經退化性疾病之醫藥組合物
|
WO2011104298A1
(en)
*
|
2010-02-24 |
2011-09-01 |
Universität Zürich |
Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids
|
WO2012024293A2
(en)
*
|
2010-08-16 |
2012-02-23 |
Genomind, Llc |
Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
|
US8258139B2
(en)
|
2010-11-08 |
2012-09-04 |
Dainippon Sumitomo Pharma Co., Ltd. |
Method of treatment for mental disorders
|
US8624052B2
(en)
*
|
2010-11-12 |
2014-01-07 |
Promentis Pharmaceuticals, Inc. |
S-t-butyl protected cysteine di-peptide analogs and related compounds
|
US9737531B2
(en)
*
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
CA2826180C
(en)
*
|
2011-01-31 |
2020-09-01 |
Serotech, Llc |
Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
|
US10583138B2
(en)
|
2012-07-12 |
2020-03-10 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
JP6265908B2
(ja)
|
2011-11-21 |
2018-01-24 |
ザ インスティチュート フォー エスノメディシン |
神経変性疾患および障害を処置するためのl−セリン組成物、方法および使用
|
US20130296430A1
(en)
*
|
2012-05-03 |
2013-11-07 |
Antonio Hardan |
Compositions and methods for treating autism and autism spectrum disorder
|
KR101499299B1
(ko)
*
|
2012-08-03 |
2015-03-09 |
연세대학교 산학협력단 |
Shank2 유전자가 결실된 자폐증 모델 형질전환마우스 및 그 용도
|
BR112015002309A2
(pt)
*
|
2012-08-07 |
2017-07-04 |
Buck Inst Res Aging |
formulação de múltiplos componentes para aprimorar a função neurológica
|
US9265458B2
(en)
|
2012-12-04 |
2016-02-23 |
Sync-Think, Inc. |
Application of smooth pursuit cognitive testing paradigms to clinical drug development
|
US9380976B2
(en)
|
2013-03-11 |
2016-07-05 |
Sync-Think, Inc. |
Optical neuroinformatics
|
AT514349B1
(de)
*
|
2013-06-12 |
2018-05-15 |
Red Bull Gmbh |
Alpha-alkylierte Aminosäuren (AAAAs)
|
WO2015031493A1
(en)
*
|
2013-08-27 |
2015-03-05 |
The Johns Hopkins University |
Amino acid treatment of seizures
|
EP2878335B1
(en)
|
2013-11-10 |
2018-01-03 |
Brainsgate Ltd. |
Implant and delivery system for neural stimulator
|
US9877951B2
(en)
|
2015-02-12 |
2018-01-30 |
College Of William And Mary |
Method for treating dementia
|
CN107636466B
(zh)
|
2015-02-18 |
2020-07-21 |
阿斯顿大学 |
先兆子痫的诊断性测定和治疗
|
IL255343B1
(en)
|
2015-05-04 |
2024-06-01 |
Confluence Pharmaceuticals Llc |
Essay formulations of acamprosate
|
EP3093043B1
(en)
|
2015-05-13 |
2018-11-14 |
Brainsgate Ltd. |
Implant and delivery system for neural stimulator
|
JP2018526345A
(ja)
*
|
2015-08-04 |
2018-09-13 |
コンフルーエンス ファーマシューティカルズ,エルエルシー |
アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
|
US20170143681A1
(en)
|
2015-11-02 |
2017-05-25 |
Apkarian Technologies Llc |
Methods and compositions for treating pain
|
CN105476976B
(zh)
*
|
2015-12-22 |
2018-09-25 |
广州瑞尔医药科技有限公司 |
药物组合物及其制备方法和应用
|
CN109475500A
(zh)
*
|
2016-05-25 |
2019-03-15 |
财团法人卫生研究院 |
用于减低***致精神病状副作用及成瘾疾患的方法与组合物
|
US9877942B1
(en)
*
|
2017-02-13 |
2018-01-30 |
Syneurx International (Taiwan) Corp. |
Co-crystals of substituted glycine and uses thereof
|
BR112019024817A2
(pt)
*
|
2017-05-25 |
2020-08-18 |
Glytech Llc. |
formulações para tratamento de distúrbio de estresse pós-traumático
|
US10226442B2
(en)
*
|
2017-07-10 |
2019-03-12 |
Syneurx International (Taiwan) Corp. |
Lithium salts of N-substituted glycine compounds and uses thereof
|
CN111491629A
(zh)
*
|
2017-11-22 |
2020-08-04 |
康塞特医药品公司 |
D-丝氨酸的氘化类似物及其用途
|
KR101952443B1
(ko)
*
|
2018-08-23 |
2019-02-26 |
주식회사 아스트로젠 |
신규한 마그네슘세리네이트 화합물 및 이의 용도
|
JP2023549174A
(ja)
*
|
2020-11-04 |
2023-11-22 |
グリアセルテック・インコーポレイテッド |
クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物
|
WO2023171106A1
(ja)
*
|
2022-03-08 |
2023-09-14 |
ソシウム株式会社 |
Tdp-43の凝集の抑制剤、tdp-43が過剰発現している細胞の細胞死の抑制剤、及びtdp-43の凝集を伴う疾患の治療又は予防剤
|